Ocumetics Technology is advancing development of its intra-ocular lens.
The Canadian research and product development company is dedicated to developing vision correction solutions with an aim to transform the field of ophthalmology via state-of-the-art intraocular lenses and other technologies.
The Calgary-based ophthalmic innovation announced this week that the first-in-human clinical study for its “revolutionary” Ocumetics Lens will take place in Mexico City, a relocation from the originally planned site in the Dominican Republic.
The lens features a proprietary design that can serve as a docking station for customized optics and evolving nanotechnologies. By linking nerves impulses with the natural mechanisms for accommodation within the human eye, this tech could address concerns such as aging eyes, hardened lenses, and cataracts.
The decision to relocate the study was based on taking “advantage of resources that better meet the company’s needs,” according to a statement from Ocumetics.
“The Ocumetics team demonstrated outstanding agility and professionalism in managing the site relocation,” remarked chief executive officer Dean Burns.
After a “detailed analysis of alternative sites and their resources,” the Alberta firm chose a site in Mexico City “because it meets all protocol requirements and offers a strong foundation for clinical studies,” according to Burns.
“Mexico City provides an ideal environment for this pivotal study with clinicians experienced in investigational studies, and an advanced infrastructure capable of supporting high-caliber ophthalmic research,” the CEO stated.
Preparations are currently underway to activate the clinical site in Mexico City, including staff training, regulatory submissions, and logistical planning, according to Ocumetics founder Garth Webb.
“With Mexico City now confirmed as the site for our first-in-human studies, we remain fully committed to moving forward with momentum and clinical rigour,” the chief scientist stated.
Ocumetics remains on track to begin human implantation of its novel accommodative intraocular lens by the end of summer.
“This milestone brings us one step closer to validating the Ocumetics Lens in a real-world clinical setting,” said Webb.
Last year, Ocumetics began manufacturing its technology and the company also unveiled a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens.
The upstart trades publicly on the TSXV as OTC.
Leave a Reply